A Study on the Immune Response and Safety of Vaccine Against Respiratory Syncytial Virus Given to Chinese Adults 18 to 59 Years of Age at Increased Risk of Respiratory Syncytial Virus Disease

NCT07220109

Status	RECRUITING
Phase	Phase 3
Sponsor	GlaxoSmithKline
Enrollment	750 participants

Key Eligibility Criteria

Inclusion (18)

- Participants who, in the opinion of the investigator, can and will comply with the requirements of the protocol.
- Written or witnessed informed consent obtained from the participant (participant must be able to understand the informed consent) prior to performance of any study-specific procedure.
- A male or female participant 18-59 YOA at the time of the study intervention administration.
- Participants should be diagnosed with at least 1 of the following medical conditions if considered medically stable* by the investigator:
- A stable condition is defined as a disease not requiring significant change (based on the investigator's opinion) in therapy or worsening during the 3 months before enrollment.

... and 13 more (see full listing online)

Exclusion (24)

- Medical conditions
- Any confirmed or suspected immunosuppressive or immunodeficient condition resulting from disease or immunosuppressive/cytotoxic therapy, based on medical history and physical examination.
- History of any reaction or hypersensitivity likely to be exacerbated by any component of the study intervention
- Unstable chronic illness.
- Any history of dementia or any medical condition that moderately or severely impairs cognition.

... and 19 more (see full listing online)

Locations (9 total)

GSK Investigational Site, Xiangtan, Hunan, China
GSK Investigational Site, Nanjing, Jiangsu, China
GSK Investigational Site, Chengdu, Sichuan, China
... and 6 more locations